SPX4,228.48-55.26 -1.29%
DIA337.04-2.88 -0.85%
IXIC12,705.22-260.13 -2.01%

BRIEF-Moleculin Concludes Phase 1B And Opens Recruitment In Phase 2 Clinical Trial Of Annamycin For Treatment Of Soft Tissue Sarcoma Lung Metastases

BRIEF-Moleculin Concludes Phase 1B And Opens Recruitment In Phase 2 Clinical Trial Of Annamycin For Treatment Of Soft Tissue Sarcoma Lung Metastases

Reuters · 07/28/2022 08:36
BRIEF-Moleculin Concludes Phase 1B And Opens Recruitment In Phase 2 Clinical Trial Of Annamycin For Treatment Of Soft Tissue Sarcoma Lung Metastases

- Moleculin Biotech Inc MBRX:

  • MOLECULIN CONCLUDES PHASE 1B AND OPENS RECRUITMENT IN PHASE 2 CLINICAL TRIAL OF ANNAMYCIN FOR THE TREATMENT OF SOFT TISSUE SARCOMA LUNG METASTASES

  • MOLECULIN BIOTECH INC - COMPANY DETERMINES RP2D TO BE 360 MG/M(2) AND WILL BEGIN PHASE 2 RECRUITMENT

  • MOLECULIN BIOTECH INC - PRELIMINARY PHASE 1B DATA DEMONSTRATED CLINICAL ACTIVITY, DEFINED AS STABLE DISEASE OR BETTER

Source text for Eikon: ID:

Further company coverage: MBRX


(Reporting by Kannaki Deka)

((Kannaki.Deka@thomsonreuters.com;))